Target intelligence / Profile preview

Squalene--hopene cyclase (SHC)

Target
SHC
Molecular classification
Enzyme, Intramolecular transferase, Isomerase, Triterpene cyclase, Membrane protein (monotopic)
01

Overview

Squalene--hopene cyclase (SHC) is a monotopic membrane-associated enzyme that catalyzes the extraordinary one-step cyclization of the linear triterpene squalene into pentacyclic hopene and, to a lesser extent, hopanol (diplopterol)[2][3][4][8]. This highly complex reaction forms five rings, nine stereocenters, and alters thirteen covalent bonds in a single enzymatic step[2][3]. SHC is widespread in bacteria and some plants, where it is essential for hopanoid biosynthesis—hopanoids are sterol-like molecules that help stabilize membranes, especially under stress[3][4]. The enzyme’s structure features a large, hydrophobic active-site cavity, lined with aromatic residues, and a nonpolar channel for substrate access[1][5]. Its mechanism is based on Brønsted acid catalysis, primarily utilizing an aspartate residue to initiate the polycyclization reaction cascade[4][5]. While SHC itself has not been directly targeted by clinically used drugs, it has been investigated as a template for developing antifungals and cholesterol-lowering agents due to its mechanistic and structural similarity to human oxidosqualene cyclase (lanosterol synthase)[4][6]. SHC serves as an important biocatalyst in synthetic chemistry for complex triterpene scaffolds[7].

Other names
Squalene hopene cyclaseSHCSqualene-hopanol cyclaseTriterpene cyclaseSQHC
02

Mechanism of action

Enzyme inhibitors (competitive active site binding), Transition-state analogs, Active-site-directed electrophiles[4].

03

Biological functions

Triterpene cyclizationConversion of squalene to hopene and hopanolSterol and hopanoid biosynthesisLipid metabolism
04

Disease associations

Other (primarily microbial physiology; roles as a direct target in human disease are not established)Potential indirect role in infection (as a target for antibacterial/antifungal agents)
05

Safety considerations

Not established for direct pharmacological targeting; potential for off-target effects in cholesterol biosynthetic pathways if cross-reactivity with homologous human enzymes (such as lanosterol synthase) occurs[4].
06

Interacting drugs

No approved drugs specifically target SHC in clinical use; enzyme inhibitors have been studied experimentally as antifungal and anticholesteremic leads[4].

Beyond the preview

Go deeper on Squalene--hopene cyclase (SHC).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Squalene--hopene cyclase (SHC).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call